Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 496
Filtrer
1.
Z Rheumatol ; 78(8): 743-752, 2019 Oct.
Article de Allemand | MEDLINE | ID: mdl-31468168

RÉSUMÉ

Rheumatoid arthritis, psoriatic arthritis and axial spondylarthritis are the most common chronic autoimmune rheumatic diseases. For all three diseases an early diagnosis and initiation of treatment is crucial. The proof of concept network study "Rheuma-VOR" is a further developed version of the predecessor project ADAPTHERA and was extended to several federal states. The aim of this prospective study is to improve the early diagnosis of rheumatoid arthritis, psoriatic arthritis and axial spondylarthritis and thus positively impact the quality of care for patients with the help of multidisciplinary coordinating centers. To date 3710 disease-specific questionnaires from patients with the suspected diagnosis of rheumatoid arthritis, psoriatic arthritis or axial spondylarthritis from 1298 different primary care providers were registered in the multidisciplinary coordination centers. A total of 1958 appointments were made with 1 of the 53 participating rheumatology specialists. In 876 patients, 1 of the 3 rheumatic diseases was diagnosed in an early stage. The waiting period was on average 42.5 days depending on the federal state, which is well below the nationwide average. It should also be noted that the coordinated cooperation and risk stratification of the Rheuma-VOR coordination centers relieved the capacity of rheumatology specialists by 1281 appointments (34.5%). In addition, the 2­week Rheuma Bus Tour and the accompanying initiatives in Rhineland-Palatinate (Rheuma-VOR screening app and the triage consultation) are showing first promising positive results.


Sujet(s)
Prestation intégrée de soins de santé/organisation et administration , Rhumatismes/diagnostic , Rhumatologie , Arthrite psoriasique/diagnostic , Polyarthrite rhumatoïde/diagnostic , Prestation intégrée de soins de santé/normes , Diagnostic précoce , Humains , Programmes nationaux de santé , Études prospectives , Rhumatologie/organisation et administration , Spondylarthrite/diagnostic
2.
Z Rheumatol ; 78(8): 722-742, 2019 Oct.
Article de Allemand | MEDLINE | ID: mdl-31468170

RÉSUMÉ

In order to reduce the prognostically relevant time interval between the initial manifestation of a rheumatic and musculoskeletal disease and diagnosis as well as the consecutive initiation of an appropriate treatment, several rheumatological centers in Germany have improved the access to initial rheumatologic evaluation by establishing early recognition/screening clinics at their respective sites. Corresponding models located at Altoetting·Burghausen, Bad Pyrmont, Berlin Buch, Duesseldorf, Heidelberg, Herne, Mannheim as well as supraregional/multicenter initiatives Rheuma Rapid, RhePort and Rheuma-VOR are presented in this overview along with the respective characteristics, potential advantages and disadvantages, but also first evaluation results of several models. The aim of this publication is to promote early detection of rheumatic and musculoskeletal diseases as one of the most important challenges in current rheumatology by encouraging further rheumatologic centers and practices to launch their own early recognition/screening consultation model on the basis of aspects presented herein.


Sujet(s)
Maladies ostéomusculaires , Rhumatismes , Rhumatologie , Diagnostic précoce , Allemagne , Humains , Maladies ostéomusculaires/diagnostic , Maladies ostéomusculaires/thérapie , Orientation vers un spécialiste , Rhumatismes/diagnostic , Rhumatismes/thérapie , Rhumatologie/méthodes
3.
J Intern Med ; 281(6): 534-553, 2017 06.
Article de Anglais | MEDLINE | ID: mdl-28295777

RÉSUMÉ

Following the continuous accumulation of evidence supporting the beneficial role of reducing low-density lipoprotein cholesterol (LDL-C) levels in the treatment and prevention of atherosclerotic cardiovascular disease and its complications, therapeutic possibilities now exist to lower LDL-C to very low levels, similar to or even lower than those seen in newborns and nonhuman species. In addition to the important task of evaluating potential side effects of such treatments, the question arises whether extremely low LDL-C levels per se may provoke adverse effects in humans. In this review, we summarize information from studies of human cellular and organ physiology, phenotypic characterization of rare genetic diseases of lipid metabolism, and experience from clinical trials. Specifically, we emphasize the importance of the robustness of the regulatory systems that maintain balanced fluxes and levels of cholesterol at both cellular and organismal levels. Even at extremely low LDL-C levels, critical capacities of steroid hormone and bile acid production are preserved, and the presence of a cholesterol blood-brain barrier protects cells in the central nervous system. Apparent relationships sometimes reported between less pronounced low LDL-C levels and disease states such as cancer, depression, infectious disease and others can generally be explained as secondary phenomena. Drug-related side effects including an increased propensity for development of type 2 diabetes occur during statin treatment, whilst further evaluation of more potent LDL-lowering treatments such as PCSK9 inhibitors is needed. Experience from the recently reported and ongoing large event-driven trials are of great interest, and further evaluation including careful analysis of cognitive functions will be important.


Sujet(s)
Cholestérol LDL/sang , Os et tissu osseux/métabolisme , Encéphale/physiologie , Maladies cardiovasculaires/prévention et contrôle , Diabète de type 2/sang , Humains , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/usage thérapeutique , Hypercholestérolémie/sang , Hypercholestérolémie/traitement médicamenteux , Phénomènes du système immunitaire , Lipoprotéines LDL/sang , Mutation , Tumeurs/sang , Proprotéine convertase 9/génétique , Facteurs de risque
4.
Z Rheumatol ; 76(Suppl 2): 46-56, 2017 Oct.
Article de Allemand | MEDLINE | ID: mdl-29330755

RÉSUMÉ

Various systemic inflammatory diseases, such as rheumatoid arthritis (RA), Sjögren's syndrome and systemic lupus erythematosus (SLE) are associated with an increased risk for the development of lymphomas. Studies on patients with RA and Sjögren's syndrome have shown that there is a clear association of the incidence of lymphoma with the severity and activity of the disease and lymphomas in particular are diseases which preferentially occur in immunosuppressed patients; therefore, knowledge of the different lymphoma subtypes, their prognosis and treatment options are important for rheumatologists. Currently, there is no evidence for an increased risk of lymphoma with the available conventional basis therapies or biologic disease-modifying antirheumatic drugs (DMARDs). The decision on how to treat a patient with previous lymphoma who requires antirheumatic treatment is more difficult as patients with previous malignancies are not included in clinical studies and in registries a bias with respect to patient selection must be taken into consideration. Decisions on the treatment approach, therefore need to be individualized and interdisciplinary management together with the treating hematologist is warranted.


Sujet(s)
Lymphomes , Rhumatismes , Antirhumatismaux/usage thérapeutique , Polyarthrite rhumatoïde , Humains , Lupus érythémateux disséminé , Lymphomes/complications , Rhumatismes/complications , Rhumatismes/traitement médicamenteux , Syndrome de Gougerot-Sjögren
5.
BMC Musculoskelet Disord ; 17: 112, 2016 Mar 01.
Article de Anglais | MEDLINE | ID: mdl-26932453

RÉSUMÉ

BACKGROUND: The number of septic total hip arthroplasty (THA) revisions is increasing continuously, placing a growing financial burden on hospitals. Orthopedic departments performing septic THA revisions have no basis for decision making regarding resource allocation as the costs of this procedure for the departments are unknown. It is widely assumed that septic THA procedures can only be performed at a loss for the department. Therefore, the purpose of this study was to investigate whether this assumption is true by performing a detailed analysis of the costs and revenues for two-stage septic THA revision. METHODS: Patients who underwent revision THA for septic loosening in two sessions from January 2009 through March 2012 were included in this retrospective, consecutive cost study from the orthopedic department's point of view. We analyzed variable and case-fixed costs for septic revision THA with special regard to implantation and explantation stay. By using marginal costing approach we neglected hospital-fixed costs. Outcome measures include reimbursement and daily contribution margins. RESULTS: The average direct costs (reimbursement) incurred for septic two-stage revision THA was €10,828 (€24,201). The difference in cost and contribution margins per day was significant (p < .001 and p = 0.019) for ex- and implantation (€4147 vs. €6680 and €429 vs. €306) while length of stay and reimbursement were comparable. CONCLUSIONS: This is the first detailed analysis of the hospital department's cost for septic revision THA performed in two sessions. Disregarding hospital-fixed costs the included variable and case fixed-costs were covered by revenues. This study provides cost data, which will be guidance for health care decision makers.


Sujet(s)
Arthroplastie prothétique de hanche/économie , Coûts et analyse des coûts/méthodes , Coûts hospitaliers , Sepsie/économie , Département hospitalier de chirurgie/économie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Arthroplastie prothétique de hanche/effets indésirables , Femelle , Humains , Mâle , Adulte d'âge moyen , Procédures orthopédiques/effets indésirables , Procédures orthopédiques/économie , Réintervention/économie , Études rétrospectives , Sepsie/étiologie , Sepsie/chirurgie
6.
Gesundheitswesen ; 77(11): 839-44, 2015 Nov.
Article de Allemand | MEDLINE | ID: mdl-25268419

RÉSUMÉ

BACKGROUND: Since the 1980s dementia residential communities (DRC) have been established as part of the health-care landscape and as an alternative to inpatient long-term nursing care. Information about (a) the residents (b) the care potential and (c) the cost of DRCs are still lacking. METHODS: A nation-wide postal questionnaire was sent to n=332 DRCs managed by n=151 organizations. The sample was based on an internet search with various combinations of search terms such as "outpatient" and "residential care communities". The questionnaire contained questions about the resident's social-demography, nursing care level and the utilization, financing and cost structures of DRCs. RESULTS: In total 81 organizations with n=88 DRCs replied to the questionnaire. Overall n=794 persons were living in these communities, most of the residents were female (80%, n=522), and 67% of the residents were older than 80 years. The nursing care level was high, 27% of the DRC residents reached the highest stage. Only 5% of the DRCs capacity was vacant. 86% of the communities stated to be able to provide nursing care for the residents until the end of their life. Almost half (48%) of the residents received money from the social welfare. The total average amount of cost per place per month was 3,265.08€ (excluding costs of services related to health insurance). CONCLUSIONS: DRCs are caring for residents with high nursing care levels. Costs of these communities vary to a large extent but are in addition comparable to inpatient long-term nursing care. Thus, interested persons should obtain information about cost, financing and care concepts. The low level of vacant capacity demonstrates the demand for DRCs in Germany. Studies with the objective to evaluate quality of care, care concepts and suitable clients for those communities are needed to develop this living concept.


Sujet(s)
Soins ambulatoires/économie , Démence/économie , Démence/thérapie , Coûts des soins de santé/statistiques et données numériques , Maisons de retraite médicalisées/économie , Maisons de repos/économie , Répartition par âge , Sujet âgé , Sujet âgé de 80 ans ou plus , Soins ambulatoires/statistiques et données numériques , Analyse coût-bénéfice/économie , Femelle , Allemagne/épidémiologie , Maisons de retraite médicalisées/statistiques et données numériques , Humains , Mâle , Maisons de repos/statistiques et données numériques , Répartition par sexe , Enquêtes et questionnaires , Résultat thérapeutique
7.
Nutr Metab Cardiovasc Dis ; 24(12): 1272-300, 2014 Dec.
Article de Anglais | MEDLINE | ID: mdl-25467217

RÉSUMÉ

Mounting evidence supports the hypothesis that functional foods containing physiologically-active components may be healthful. Longitudinal cohort studies have shown that some food classes and dietary patterns are beneficial in primary prevention, and this has led to the identification of putative functional foods. This field, however, is at its very beginning, and additional research is necessary to substantiate the potential health benefit of foods for which the diet-health relationships are not yet scientifically validated. It appears essential, however, that before health claims are made for particular foods, in vivo randomized, double-blind, placebo controlled trials of clinical end-points are necessary to establish clinical efficacy. Since there is need for research work aimed at devising personalized diet based on genetic make-up, it seems more than reasonable the latter be modeled, at present, on the Mediterranean diet, given the large body of evidence of its healthful effects. The Mediterranean diet is a nutritional model whose origins go back to the traditional dietadopted in European countries bordering the Mediterranean sea, namely central and southern Italy, Greece and Spain; these populations have a lower incidence of cardiovascular diseases than the North American ones, whose diet is characterized by high intake of animal fat. The meeting in Naples and this document both aim to focus on the changes in time in these two different models of dietary habits and their fall out on public health.


Sujet(s)
Maladies cardiovasculaires/épidémiologie , Maladies cardiovasculaires/prévention et contrôle , Aliment fonctionnel , Animaux , Restriction calorique , Enquêtes sur le régime alimentaire , Régime méditerranéen , Épigenèse génétique , Comportement alimentaire , Humains , Nutrigénomique
8.
Dtsch Med Wochenschr ; 139(50): 2597-601, 2014 Dec.
Article de Allemand | MEDLINE | ID: mdl-25469695

RÉSUMÉ

HISTORY AND CLINICAL FINDINGS: A 51-year-old female patient with history of longterm drug abuse, was admitted to our hospital with large, stocking-shaped areas of painful, non-displaceable confluent bruising reaching up to the groin. INVESTIGATIONS: The emergency laboratory tests showed leucopenia, thrombocytopenia and anemia as well as a distinct protein C deficiency. DIAGNOSIS, TREATMENT AND COURSE: Purpura fulminans was diagnosed and treated with an initial dose of protein C. The patient survived and the skin necrosis can be treated. CONCLUSION: Purpura fulminans is an internistic and dermatological emergency situation which can lead to shock through consumptive coagulopathy. The serious course of disease can be prevented by rapid treatment with protein C.


Sujet(s)
Urgences , Déficit en protéine C/diagnostic , Purpura fulminans/diagnostic , Diagnostic différentiel , Femelle , Humains , Adulte d'âge moyen , Pronostic , Protéine C/administration et posologie , Déficit en protéine C/sang , Déficit en protéine C/traitement médicamenteux , Purpura fulminans/sang , Purpura fulminans/traitement médicamenteux , Troubles liés à une substance/complications
9.
Pathologe ; 35(2): 127-40; quiz 141-2, 2014 Mar.
Article de Allemand | MEDLINE | ID: mdl-24619523

RÉSUMÉ

Carcinomas of the oropharynx with association to high-risk types of human papillomavirus (HPV) have been identified as a new tumour entity with favourable prognosis, distinct from classical nicotine- and alcohol-associated carcinoma. They develop through oncogenic transformation of the basal cells of reticulated cryptal epithelium of the palatinal tonsils and the base of the tongue. Positivity for HPV strongly correlates with an atypical, non-keratinizing histological differentiation and cystic transformation of lymph node metastases. Strong immunohistological positivity for p16 reliably detects transcriptionally active infection with high-risk HPV. Hence, p16 staining has been regarded as an effectual diagnostic tool in the appropriate setting. Frequent nodal metastasation as well as considerable size of (cystic) metastases, and frequent small size as well as submucosal location of primary tumours all contribute to frequent initial manifestation of cervical cancer of unknown primary (CUP). In a situation of CUP diagnostic testing for HPV (in negative cases in addition to EBV) is recommended in lymph node metastases, due to the high predictive value for the localization of occult primary carcinomas. Intense clinicopathological cooperation is mandatory for improved detection of small, occult primary carcinomas. The relevance of this new carcinoma entity will increase, as the incidence continues to increase worldwide.


Sujet(s)
Papillomavirus humain de type 16/pathogénicité , Métastases d'origine inconnue/anatomopathologie , Métastases d'origine inconnue/virologie , Tumeurs de l'oropharynx/anatomopathologie , Tumeurs de l'oropharynx/virologie , Infections à papillomavirus/anatomopathologie , Infections à papillomavirus/virologie , Transformation cellulaire néoplasique/anatomopathologie , Transformation cellulaire virale/physiologie , Humains , Noeuds lymphatiques/anatomopathologie , Métastase lymphatique/anatomopathologie , Tumeurs de l'oropharynx/secondaire , Partie orale du pharynx/anatomopathologie , Partie orale du pharynx/virologie , Terminologie comme sujet , Tumeurs de la langue/anatomopathologie , Tumeurs de la langue/secondaire , Tumeurs de la langue/virologie , Tumeurs de l'amygdale/anatomopathologie , Tumeurs de l'amygdale/secondaire , Tumeurs de l'amygdale/virologie
10.
Arch Orthop Trauma Surg ; 134(3): 413-20, 2014 Mar.
Article de Anglais | MEDLINE | ID: mdl-24477287

RÉSUMÉ

INTRODUCTION: Aseptic loosening is one of the most common intermediate and long-term complications after total hip replacement (THR). These complications cause suffering and require expensive revision surgery. Little concrete data on direct costs are available from the hospital's, moreover operating department's perspective. We here provide a detailed analysis of the costs of THR revision and relate them to reimbursement underlying the German diagnosis-related groups (DRG) system. MATERIALS AND METHODS: Major cost parameters were identified using for orientation the cost matrix of the German Institute for Hospital Reimbursement (InEK GmbH). We then retrospectively analysed the major direct costs of aseptic revision THR in terms of contribution margins I and II. The analysis included a total of 114 patients who underwent aseptic revision from 1 January 2009 to 31 March 2012. Data were retrieved from the hospital information system and patient records. All costs of surgery, diagnostic tests, and other treatments were calculated as purchase prices in EUR. The comparative analysis of direct costs and reimbursements was done for DRG I46A and I46B from the hospital's, especially treating department's rather than the society or healthcare insurance's perspective. RESULTS: The average direct cost incurred by the hospital for a THR revision was 4,380.0. The largest share was accounted for surgical costs (62.7 % of total). Implant and staff costs were identified as the most important factors that can be influenced. The proportion of the daily contribution margin that was left to cover the hospital's indirect cost decreased with the relative cost weight of the DRG to which a patient was assigned. CONCLUSION: Our study for the first time provides a detailed analysis of the major direct case costs of THR revision for aseptic loosening from the provider's perspective. Our findings suggest that these revision operations could be performed cost-beneficially by the operating unit. From an economic perspective, cases with higher cost weights are more favorable for a hospital. These results need to be confirmed in multicenter studies.


Sujet(s)
Arthroplastie prothétique de hanche/effets indésirables , Arthroplastie prothétique de hanche/économie , Remboursement par l'assurance maladie/économie , Sujet âgé , Sujet âgé de 80 ans ou plus , Arthroplastie prothétique de hanche/statistiques et données numériques , Groupes homogènes de malades/économie , Femelle , Allemagne , Coûts hospitaliers , Humains , Prothèse articulaire/effets indésirables , Prothèse articulaire/économie , Mâle , Adulte d'âge moyen , Défaillance de prothèse , Réintervention/économie , Études rétrospectives
11.
Ann Rheum Dis ; 73(5): 890-6, 2014 May.
Article de Anglais | MEDLINE | ID: mdl-23592712

RÉSUMÉ

OBJECTIVES: To investigate the contribution of genetic polymorphisms of toll like receptor (TLR) 9 and related genes on the susceptibility and clinical manifestation of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV). METHODS: Four single nucleotide polymorphisms (SNPs) in TLR9 were genotyped in 863 German AAV cases and 1344 healthy controls. Significant results were replicated in a cohort of 426 Dutch and British AAV cases. 11 polymorphisms in TLR9 related genes were studied concomitantly. RESULTS: A strong association of TLR9 genotypes and haplotypes with granulomatosis with polyangiitis was observed as well as a contrariwise association with microscopic polyangiitis. The association was confirmed when cases were compared according to ANCA status rather than to clinical entity. This was partly replicated in the second cohort leading to a striking overall difference in TLR9 allele/haplotype frequencies between proteinase 3 (PR3) ANCA+ and myeloperoxidase (MPO) ANCA+ cases (p=0.00000398, pc=0.000016, OR 1.68 (95% CI 1.35 to 2.1) for rs352140; p=0.000011, pc=0.000044, OR 1.64 (95% CI 1.31 to 2.04) for a 3-SNP haplotype). No significant association or epistatic effect was detected for TLR9 related genes: interleukin 6, interleukin 23 receptor, myeloid differentiation primary response 88, TNF receptor-associated factor 6, interleukin-1 receptor-associated kinase 4, discs large homolog 5 and nucleotide-binding oligomerisation domain containing 2. CONCLUSIONS: We provide further evidence that PR3-ANCA+ AAV differs genetically from MPO-ANCA+ AAV. TLR9 signalling may be involved in disease pathology, favouring models of infectious agents triggering AAV development.


Sujet(s)
Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/génétique , Prédisposition génétique à une maladie/génétique , Récepteur-9 de type Toll-like/génétique , Adulte , Études cas-témoins , Femelle , Génotype , Humains , Déséquilibre de liaison , Mâle , Polymorphisme de nucléotide simple
12.
13.
Nutr Metab Cardiovasc Dis ; 23(8): 732-6, 2013 Aug.
Article de Anglais | MEDLINE | ID: mdl-22795295

RÉSUMÉ

BACKGROUND AND AIM: The complete absence of the lysosomal acid lipase (LAL) enzyme function causes Wolman's Disease that is fatal within the first six months of life. Subtotal defects cause Cholesteryl ester storage disease (CESD), an autosomal recessive disorder leading to hepatic steatosis, fibrosis, micronodular cirrhosis, combined hyperlipidemia with low HDL-cholesterol, increased risk for atherosclerosis, premature death. Since the frequency of the Exon 8 splice junction mutation (c.894 G > A, E8SJM), the CESD leading mutation, is not rare in the general population (allele frequency 0.0025), we investigated the impact of this mutation on serum lipid profile in E8SJM carriers. METHODS AND RESULTS: We collected E8SJM carriers both form genetic study-population analysis and from Outpatient Lipid Clinics and then we assessed their serum lipid profile. We found thirteen individuals heterozygote for E8SJM. Most of them were Germans, three Spanish and two Italian. We found a significant increase in total cholesterol levels in both sexes with E8SJM mutation, leading to a significant increase in LDL cholesterol in males. CONCLUSIONS: Our results show that LAL E8SJM carriers have an alteration in lipid profile with a Polygenic Hypercholesterolemia phenotype, leading to an increase in cardiovascular risk profile.


Sujet(s)
Cholestérol/sang , Hétérozygote , Mutation , Sterol Esterase/génétique , Maladies cardiovasculaires/génétique , Études cas-témoins , Femelle , Allemagne , Humains , Italie , Mâle , Phénotype , Facteurs de risque , Espagne ,
14.
Clin Exp Rheumatol ; 30(1): 45-50, 2012.
Article de Anglais | MEDLINE | ID: mdl-22274638

RÉSUMÉ

OBJECTIVES: Psoriatic arthritis (PsA) may progress to joint damage. Determining clinical predictors of joint damage assessed by radiography is important. The aim of this study was to determine clinical factors as possible predictors for radiological damage in hands and feet of PsA patients with a 12-month follow-up. METHODS: We conducted a retrospective study on 53 PsA patients who were taking disease-modifying anti-rheumatic drugs (DMARDs) and/or tumour necrosis factor (TNF)-alpha-blockers at a fixed dosage. The patients were observed in 118 follow-up visits (intervals of 12 months ± 3 months), according to a clinical and radiological protocol which included the documentation of the number of swollen and tender joints in hands and feet, the applied therapy, psoriasis, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and global health assessment. Outcome was defined as radiographic damage of hands and feet (Ratingen score). For the statistical analysis the Chi-Square test for 2x2 crosstables (with Fisher's correction, as required) was used. RESULTS: Progressive radiological damage was more frequent among patients with an increasing swollen joint count (8 of 26 visits; 30.8%) than among those with a stable or decreased number of swollen joints (5 of 89 visits; 5.6%; p=0.001). The analysis of the patients stratified into the different treatment modalities resulted in a significant higher rate of radiological progress (20.8%) in patients on DMARD therapy compared with TNF-alpha blocking agents (0%) (p=0.009). CONCLUSIONS: During a 12-month follow-up of PsA patients, an increasing number of swollen joints heralds progression of radiological damage. TNF-alpha-blocker therapy appears to be superior to DMARDs in the protection from radiological progress.


Sujet(s)
Arthrite psoriasique/imagerie diagnostique , Pied/imagerie diagnostique , Main/imagerie diagnostique , Articulations/anatomopathologie , Adulte , Sujet âgé , Antirhumatismaux/usage thérapeutique , Arthrite psoriasique/traitement médicamenteux , Arthrite psoriasique/anatomopathologie , Évolution de la maladie , Femelle , Études de suivi , Pied/anatomopathologie , Main/anatomopathologie , Humains , Mâle , Adulte d'âge moyen , Pronostic , Radiographie , Études rétrospectives , Résultat thérapeutique , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs
15.
Best Pract Res Clin Rheumatol ; 25(3): 423-34, 2011 Jun.
Article de Anglais | MEDLINE | ID: mdl-22100290

RÉSUMÉ

The syndrome of synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) includes a rare group of chronic, relapsing, inflammatory osteoarticular disorders that is conventionally associated with manifestations in the skin. Diagnostic dilemmas can arise due to incomplete manifestations or confusion generated through mimicking of other conditions, such as osteomyelitis. The aetiology of this syndrome remains unclear, but probably involves genetic, immunological and infectious mechanisms. The possible pathogenetic role of infectious agents in genetically predisposed individuals, resulting in a 'reactive osteitis', has been suggested because microbes such as Propionibacterium acnes have been recovered from bone biopsy samples. However, this hypothesis has not been demonstrated as yet. Current knowledge with regard to treatment of this syndrome is based on results reported from small case studies and, thus, is still empiric. The use of antibiotics, instituted based on the isolation of Propionibacterium acnes, has been reported to show conflicting results. Promising results for potential future application have recently been reported for treatment of SAPHO with bisphosphonates and antagonists of tumour necrosis factor-α. This review aims to evaluate the existing knowledge on the SAPHO syndrome and to provide information on symptoms, diagnosis and treatment options for this disease.


Sujet(s)
Syndrome SAPHO/microbiologie , Syndrome SAPHO/diagnostic , Syndrome SAPHO/traitement médicamenteux , Humains
16.
Pathologe ; 32(5): 391-8, 2011 Sep.
Article de Allemand | MEDLINE | ID: mdl-21935761

RÉSUMÉ

About 7-8% of all human cancers are thought to be related to infections with high-risk (HR) human papilloma virus (HPV). Besides cervical cancer, especially squamous cell carcinomas of the anogenital and oropharyngeal regions are associated with HR-HPV. Transmission of HPV is due to sexual activity. Harald zur Hausen was awarded in 2008 with the Nobel price in medicine for the establishment of a causal link between certain HPV infections and cervical cancer. Meanwhile potent prophylactic vaccines are available to prevent infections with HPV-16 and HPV-18, the two most frequently observed HR HPV types worldwide. On molecular grounds a persistent HPV infection is the central risk factor for the development of HPV-associated neoplasias. Continued expression of the viral E6 and E7 oncogenes disrupts cell cycle control mechanisms in infected cells, thereby gaining limitless proliferative capacity and resistance against apoptotic signals. However acquisition of mutations and genomic instability might cause malignant transformation in these cells.


Sujet(s)
Carcinome épidermoïde/anatomopathologie , Transformation cellulaire néoplasique/anatomopathologie , Tumeurs cutanées/anatomopathologie , Apoptose/physiologie , Biopsie , Prolifération cellulaire , Protéines de liaison à l'ADN/analyse , Femelle , Tumeurs de l'appareil génital féminin/anatomopathologie , Tumeurs de l'appareil génital mâle/anatomopathologie , Papillomavirus humain de type 16 , Papillomavirus humain de type 18 , Humains , Mâle , Protéines des oncogènes viraux/analyse , Tumeurs de l'oropharynx/anatomopathologie , Protéines E7 de papillomavirus/analyse , Infections à papillomavirus/anatomopathologie , Protéines de répression/analyse , Facteurs de risque , Peau/anatomopathologie , Tumeurs du col de l'utérus/anatomopathologie
17.
Radiologe ; 50(4): 349-54, 2010 Apr.
Article de Allemand | MEDLINE | ID: mdl-20333502

RÉSUMÉ

PURPOSE: The immunohistochemical expression of somatostatin receptor (SSTR) subtype 2 was compared to quantitative (68)Ga-DOTATATE PET in neuroendocrine tumors (NET). MATERIAL AND METHODS: In 27 patients suffering from metastatic NET the expression of somatostatin receptors (SSTR, score 0-3) and the Ki-67 index were assessed. The immunohistochemical findings were compared with the (68)Ga-DOTATATE PET uptake in these tumors using the SUV(max) (standardized uptake value). Both values were compared with the Ki-67 proliferation index. RESULTS: The SUV(max) in NET without SSTR expression was significantly lower compared to those with SSTR expression (p <0.05), even though 3 out of 5 NETs with a score of 0 showed a high uptake of (68)Ga-DOTATATE. The SUV(max) correlated significantly (r=0.40, p <0.05) with the score of immunohistochemical SSTR expression (negative, score 0, moderate, score 1 and high, scores 2 and 3). The Ki-67 index correlated inversely with the SSTR expression score (r=-0.42, p <0.05), but not significantly with the SUV(max) (r=-0.33, p=0.11). CONCLUSION: (68)Ga-DOTATATE uptake was moderately correlated with the results of immunohistochemical SSTR analyses. However, SSTR negative NET may show high uptake of (68)Ga-DOTATATE.


Sujet(s)
Tumeurs neuroendocrines/imagerie diagnostique , Tumeurs neuroendocrines/métabolisme , Composés organométalliques/pharmacocinétique , Tomographie par émission de positons/méthodes , Récepteur somatostatine/métabolisme , Tomodensitométrie/méthodes , Adulte , Sujet âgé , Femelle , Analyse de profil d'expression de gènes/méthodes , Humains , Mâle , Adulte d'âge moyen , Radiopharmaceutiques/pharmacocinétique , Reproductibilité des résultats , Sensibilité et spécificité , Distribution tissulaire
18.
Digestion ; 81(4): 246-51, 2010.
Article de Anglais | MEDLINE | ID: mdl-20110711

RÉSUMÉ

BACKGROUND/AIMS: Defective p53-mediated apoptosis and cell cycle control have been implicated in the immunopathogenesis of Crohn's disease (CD). Since common functional variants of p53 (SNP72 G/C) and its key negative regulator mdm2 (SNP309 T/G) have been reported to affect cellular apoptotic and cell cycle arrest capacities, we assessed the effects of these variants on CD susceptibility and their relationship to NOD2/CARD15 as a well-established genetic CD risk factor. METHODS: The variants SNP72 G/C and SNP309 T/G were genotyped in 149 European CD patients and 478 healthy controls. Subgroup analysis was performed in relation to NOD2/CARD15 status and to demographic/clinical characteristics. RESULTS: The p53 SNP72 CC genotype tended to be less frequent in CD. This reached statistical significance only in the male cohort (0 vs. 7.3%; p = 0.037). Genotype and allele frequencies of both single-nucleotide polymorphisms (SNPs) were otherwise not significantly different. In the combined genotypic analysis, the genotype p53 SNP72 CC was significantly underrepresented in mdm2 SNP309 TT homozygotes (0 vs. 9.7%; p = 0.034). No association was observed between NOD2/CARD15 and the respective SNPs. CONCLUSION: We report on a gender-specific protective effect of the low-apoptotic SNP72 CC genotype, and a gender-unrestricted genotypic interaction between SNP309 TT and SNP72 CC, which, for the first time, links sequence variation of the p53/mdm2 network to CD, independent of NOD2/CARD15.


Sujet(s)
Apoptose/génétique , Maladie de Crohn/génétique , Prédisposition génétique à une maladie , Protéines proto-oncogènes c-mdm2/génétique , Protéine p53 suppresseur de tumeur/génétique , Adulte , Allèles , Études cas-témoins , Intervalles de confiance , Maladie de Crohn/épidémiologie , Maladie de Crohn/anatomopathologie , Femelle , Régulation de l'expression des gènes , Variation génétique , Génotype , Humains , Mâle , Adulte d'âge moyen , Odds ratio , Polymorphisme de nucléotide simple , Pronostic , Valeurs de référence , Appréciation des risques , Facteurs sexuels
19.
HNO ; 58(4): 371-3, 2010 Apr.
Article de Allemand | MEDLINE | ID: mdl-19565206

RÉSUMÉ

Sarcoidosis is a granulomatous systemic disease of unknown etiology. Besides the landmark pulmonary lesions, extrathoracic manifestations of the disease can also occur. We report the case of a 53-year-old woman with an obscure swelling of both submandibular compartments. The radiological and pathohistological evaluations confirmed the uncommon diagnosis of sarcoidosis of the submandibular compartment. The tumor in each compartment consisted of a huge lymph node conglomerate respectively displacing the submandibular gland. The major salivary glands and the thorax were not involved.


Sujet(s)
Maladies lymphatiques/diagnostic , Sarcoïdose/diagnostic , Maladie de la glande sous-maxillaire/diagnostic , Diagnostic différentiel , Femelle , Humains , Adulte d'âge moyen
20.
Clin Exp Rheumatol ; 27(4): 615-9, 2009.
Article de Anglais | MEDLINE | ID: mdl-19772793

RÉSUMÉ

OBJECTIVE: This study examines two common, functional, single nucleotide polymorphisms (SNP) in the genes coding the human homolog of murine-double-minute-2 (MDM2) and p53 in patients with rheumatoid arthritis (RA) based on the hypothesis that p53 may be an important negative regulator of the pro-inflammatory transcription factor nuclear factor kappa b (NFKappaB). METHODS: Genomic DNA was obtained from 221 patients with RA who fulfilled at least 4 ACR criteria and from 521 healthy controls. Mdm2 SNP309 and p53 P72R were genotyped by polymerase chain reaction and restriction enzyme analysis. RESULTS: In RA patients the frequencies of the mdm2 SNP309 G allele and both G-containing genotypes were significantly reduced (G allele: OR: 0.75, 95% CI: 0.59-0.95, p=0.016; genotype TG: OR: 0.71, 95% CI: 0.50-1.00; genotype GG: OR. 0.58, 95% CI: 0.34-0.99; both: p=0.049). Concerning p53 P72R, no differences in allele or genotype frequencies were detected. A combined analysis of both polymorphisms revealed a significant interaction between them (p=0.046). In individuals carrying >1 p53 72R allele, MDM2 had a protective effect, whereas in individuals homozygous for p53 72P, MDM2 had the opposite effect. CONCLUSION: The function of MDM2 depends on the p53 P72R genotype, resulting in either an increased or reduced risk for RA. We suggest that in most cases MDM2 stabilizes the conformation of p53, whereas in p53 PP-positive subjects MDM2 supports the degradation of p53.


Sujet(s)
Polyarthrite rhumatoïde/génétique , Prédisposition génétique à une maladie , Polymorphisme de nucléotide simple , Protéines proto-oncogènes c-mdm2/génétique , Adolescent , Adulte , Sujet âgé , Allèles , Études cas-témoins , Femelle , Fréquence d'allèle , Humains , Mâle , Adulte d'âge moyen , Protéine p53 suppresseur de tumeur/génétique , Jeune adulte
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE